Exelixis, Inc. (EXEL) Stock Forecast & Price Target
Price as of Nov 16, 2026 (intraday, delayed) · Analyst estimates retrieved Nov 11, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)
Revenue and earnings estimates published by analysts covering Exelixis, Inc. (EXEL), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.
For Exelixis, Inc., analysts forecast revenue rising from $2.32B in 2026 to $3.48B in 2031; the average estimate for 2031 earnings per share is $5.95; with published estimates ranging from $5.40 to $6.30; 12 analysts contribute to these figures. These are forecasts published by analysts, not results.
Analyst price targets
A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.
Revenue forecast (USD)
The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.
Earnings per share forecast
Exelixis, Inc. (EXEL) forecast — frequently asked questions
What is the analyst price target for Exelixis, Inc.?
Analysts covering Exelixis, Inc. (EXEL) have a consensus price target of $53.00, 21.8% below the current price of $67.81. Published targets range from $49.00 to $60.00. A price target is a forecast, not a measure of value, and targets are revised often.
What are analysts forecasting for Exelixis, Inc.'s earnings?
The average analyst estimate for Exelixis, Inc. (EXEL) earnings per share in 2031 is 5.95, with individual estimates between 5.40 and 6.30.
How much revenue is Exelixis, Inc. expected to make?
Analysts forecast Exelixis, Inc. (EXEL) revenue of $3.48B in 2031, based on 5 published estimates.
How many analysts cover EXEL?
12 analysts contribute estimates for Exelixis, Inc. (EXEL). Thin coverage makes an average less reliable.
Analyst forecasts for other Biotechnology stocks
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.